Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports


Current news and events

Awarded 9 million NOK to study autophagy in prostate cancer

Nikolai Engedal
Nikolai Engedal

Nikolai Engedal was recently awarded 9 million NOK in Open project support from The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) 2020 call. The project aims to unravel the role of autophagy in prostate cancer formation and progression, to discover prognostic autophagy-related gene signatures and markers, and to identify autophagy-modulating drugs that can reduce cancer cell aggressiveness. Engedal is now starting up a project group in Eivind Hovig’s group at the Department of Tumor Biology.

Project from Weyergangs project group admitted to SPARK Norway

Anette Weyergang
Anette Weyergang

In the project entitled "A Novel Biomarker for Antibody Drug Conjugates" Weyergang and her team seeks to develop a diagnostic tool for better stratification of patients to novel targeted therapeutics including antibody drug conjugates.

SPARK is a Life Science`s innovation program build to increase the success rate of projects with high potential impact, addressing critical unmet needs. Project teams admitted to SPARK will be educated and advised on relevant processes for commercialization of their idea. They will also receive financial support (up to 500 000 NOK per year- maximum two years based on the accomplishment of milesones). 

Sigrid S. Skånland appointed project group leader

Sigrid S. Skånland
Sigrid S. Skånland

Researcher Sigrid S. Skånland has been appointed project group leader in the group of Kjetil Taskén at the Department of Cancer Immunology, Institute for Cancer Research.
Her research group will focus on developing functional precision medicine for haematological cancers, in particular the B-cell malignancy chronic lymphocytic leukemia (CLL). By performing functional analyses including ex vivo drug sensitivity screening and single cell signaling analyses, her aim is to identify biomarker signatures that can predict treatment outcomes for the individual patient.

Announcement: Excellent Researcher Award and Early Career Award 2021:Nominate an outstanding scientist at Oslo University Hospital

Last year's (2020) award winners, from left: Hoffmann-Vold, Bretthauer and Kristianslund
Last year's (2020) award winners, from left: Hoffmann-Vold, Bretthauer and Kristianslund

Oslo University Hospital hereby announce research awards in the following two catagories for 2021:

  • Excellent Researcher Award (one prize, 300.000 NOK)
  • Early Career Award (two prizes of 150.000 NOK each)

Closing date for nominations: March 1st 2021.


In Nature:The Olweus lab reports that translational mistakes in cancer can be targets of immunotherapy

Maarja Laos (left) and Johanna Olweus
Maarja Laos (left) and Johanna Olweus

A combined research effort by scientists at the Weizmann Institute of Science in Israel and researchers at the Netherlands Cancer Institute in Amsterdam and Oslo University Hospital/University of Oslo, Norway, shows exactly how tumors can overcome hurdles that occur when starved for certain building blocks used in protein synthesis.  
Update: The paper has recently received attention in "Nature Reviews Cancer".

Units and subpages

View all subunitsHide all subunits